Latest Content

Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.

CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.

The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.

CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.

Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.

Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.

Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.

The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.

The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.

Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.

A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.

Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.

Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.

The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.

The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.

Obesity may increase breast cancer risk partly by removing a natural defense.

Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.

KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.

Alexandra Leary, MD, PhD, discusses TEDOVA's design, the safety profile of OSE2101, and implications for maintenance in ovarian cancer.

ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.

Osimertinib plus platinum-pemetrexed showed a numerical PFS and OS advantage over osimertinib alone regardless of baseline TP53 status in FLAURA2.

The FDA has approved lutetium Lu 177 dotatate injection for SSTR-positive GEP-NETs, including foregut, midgut, and hindgut NETs.

Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.

Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.

Dana-Farber Cancer Institute is launching Solavia Decision Suite to bring clinical expertise and evidence-based treatment pathways directly into clinicians’ workflows.

The FDA indication for adagrasib plus cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer has been removed.

The updated tarlatamab label reduces post-infusion monitoring after each of the first two doses to 6 to 8 hours, down from 22 to 24 hours.

TLX101-Px, an FET-PET imaging agent, was FDA approved to differentiate treatment-related changes from recurrent or progressive glioma.

The FDA approved aminolevulinic acid hydrochloride plus PDT for the treatment of superficial basal cell carcinoma.

TKI-based regimens were associated with higher rates of disease control in metastatic translocation renal cell carcinoma.

Jay M. Lee, MD, discusses how NAUTIKA1 compares with ALNEO and LORIN, why full genomic profiling is now essential before starting chemoimmunotherapy, and how tumor boards will manage early-stage NSCLC in 5 years.

Jay M. Lee, MD, discusses the primary analysis of the ALK+ cohort of NAUTIKA1, what MPR status adds to risk stratification, and whether neoadjuvant alectinib is ready for patients today.

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

The final OS analysis of PAPILLON did not reach statistical significance in the ITT population, but a pre-specified crossover-adjusted analysis showed a 43% reduction in the risk of death.

An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.